References
- 1. WHO. (1999). Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 6(1), 35-47.
- 2. McHutchison, J.G., Manns, M.P., Muir, A.J., Terrault, N.A., Jacobson, I.M., Afdhal, N.H., Heathcote, E.J., Zeuzem, S., Reesink, H.W., Garg, J., Bsharat, M., George, S., Kauffman, R.S., Adda, N., Di Bisceglie, A.M. & Team, P.S. (2010). Telaprevir for previously treated chronic HCV infection. N Engl J Med. 362(14), 1292-1303. doi: 10.1056/NEJMoa0908014.
- 3. Muir, A.J., Poordad, F.F., McHutchison, J.G., Shiffman, M.L., Berg, T., Ferenci, P., Heathcote, E.J., Pawlotsky, J.M., Zeuzem, S., Reesink, H.W., Dusheiko, G., Martin, E.C., George, S., Kauffman, R.S. & Adda, N. (2011). Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 54(5), 1538-1546. doi: 10.1002/hep.24549.
- 4. Perry, C.M. (2012). Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 72(5), 619-641. doi: 10.2165/11208370-000000000-00000.
- 5. Ascione, A. (2012). Boceprevir in chronic hepatitis C infection: a perspective review. Ther Adv Chronic Dis. 3(3), 113-121. doi: 10.1177/2040622312441496.
- 6. Leroy, V., Serfaty, L., Bourliere, M., Bronowicki, J.P., Delasalle, P., Pariente, A., Pol, S., Zoulim, F., Pageaux, G.P. & French Association for the Study of the, L. (2012). Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int. 32(10), 1477-1492. doi: 10.1111/j.1478-3231.2012.02856.x.
- 7. Matthews, S.J. & Lancaster, J.W. (2012). Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther. 34(9), 1857-1882. doi: 10.1016/j.clinthera.2012.07.011.
- 8. Claxton, A.J., Cramer, J. & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 23(8), 1296-1310.
- 9. Buring, S.M., Winner, L.H., Hatton, R.C. & Doering, P.L. (1999). Discontinuation rates of Helicobacter pylori treatment regimens: a metaanalysis. Pharmacotherapy. 19(3), 324-332.
- 10. Connor, J., Rafter, N. & Rodgers, A. (2004). Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 82(12), 935-939. doi: /S0042-96862004001200010.
- 11. Iskedjian, M., Einarson, T.R., MacKeigan, L.D., Shear, N., Addis, A., Mittmann, N. & Ilersich, A.L. (2002). Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a metaanalysis. Clin Ther. 24(2), 302-316.
- 12. Richter, A., Anton, S.F., Koch, P. & Dennett, S.L. (2003). The impact of reducing dose frequency on health outcomes. Clin Ther. 25(8), 2307-2335.
- 13. Yildiz, A., Pauler, D.K. & Sachs, G.S. (2004). Rates of study completion with single versus split daily dosing of antidepressants: a metaanalysis. J Affect Disord. 78(2), 157-162.
- 14. van Dulmen, S., Sluijs, E., van Dijk, L., de Ridder, D., Heerdink, R. & Bensing, J. (2007). Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 7, 55. doi: 10.1186/1472-6963-7-55.
- 15. Special report: interventions to improve patient adherence with medications for chronic cardiovascular disorders. (2003). TEC Bull (Online). 20(3), 30-32.
- 16. DiMatteo, M.R. (2004). Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 42(3), 200-209.
- 17. Vergouwen, A.C., Bakker, A., Katon, W.J., Verheij, T.J. & Koerselman, F. (2003). Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry. 64(12), 1415-1420.